Sanofi (SAN) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic and financial overview

• Achieved 8.7% sales growth year-to-date, targeting double-digit growth through 2030 and beyond, supported by a diversified portfolio and new blockbusters like Altuviiio.

• Transformation includes exiting consumer health, major cost reductions, and focusing on R&D-led growth, with 30,000 fewer employees and fewer manufacturing sites.

• Profitable growth targeted, with ROI and EPS expected to outpace sales, supported by disciplined spending, increasing gross margins, and strong capital allocation including a €5bn share buyback and increased dividend.

• Business development remains disciplined, with a focus on supplementing the early-stage pipeline, maintaining a strong balance sheet, and active portfolio management including divestments and acquisitions.

• Achieved €3.9bn sales from 12 newly launched medicines and vaccines, with one new blockbuster and three new medicines and vaccines introduced in 2025.

R&D and pipeline updates

• Multiple late-stage projects in rare diseases, oncology, neurology, immunology, and vaccines, with several in phase 3 and major upcoming readouts expected in the first half of the year.

• Amlitelimab COAST 2 and SHORE studies are key near-term milestones, with positive data in atopic dermatitis and a favorable safety profile.

• Pipeline includes multiple mechanisms in atopic dermatitis, asthma, GI, and new assets like STAT6, bispecifics, and brivekimig entering the clinic.

• Duvakitug is positioned as a potential best-in-class molecule in IBD, with key data expected later in the year and new phase 3 programs initiated.

• Frexalimab in MS shows strong lesion data and a favorable safety profile, with a focus on disability endpoints for future differentiation.

Market and policy environment

• U.S. pricing negotiations have led to manageable impacts, with cost avoidance strategies and removal of certain tariffs for 2026.

• The administration's focus on insurers may present both opportunities and challenges for pharma partnerships.

• European access to new medicines remains a concern, with 54% of EMA-approved drugs unavailable in Europe, highlighting the need for better innovation rewards.

• Vaccine policy changes and misinformation present challenges, but strong real-world evidence for Beyfortus supports continued growth and access.